Stallion India Fluorochemicals Secures Land for HFO Plant in Rajasthan, Eyes ₹200 Crore Investment
Stallion India Fluorochemicals received land allotment approval from RIICO for a new HFO manufacturing plant in Rajasthan. The company plans an investment of approximately ₹200 crore, with work expected to start in 2027. This expansion aims to enhance their product portfolio and achieve a 30-35% revenue CAGR over three years.
The land acquisition and planned investment for a new HFO manufacturing plant represent a major strategic expansion that will likely have a significant impact on the company's future operations, product offerings, and financial performance.
The announcement details a significant step forward in expanding the company's manufacturing capabilities with a new plant and a substantial investment, which is expected to drive future revenue growth.
Stallion India Fluorochemicals Limited (SIFL) has received approval from RIICO for land allotment to establish its proposed Hydrofluorolefin (HFO) manufacturing plant in Rajasthan. The land, located in the RIICO Industrial Area, Ukhaliya, District Bhilwara, comprises three adjoining plots totaling approximately 122,543 sq. mtrs. This consolidated landholding will enable the development of a fully integrated manufacturing layout and facilitate operational synergies, improved efficiencies, and cost optimization.
Mr. Shazad Rustomji, Managing Director & CEO of SIFL, highlighted that HFOs represent the next generation of low-global-warming-potential refrigerant technologies, which will enhance the company's product portfolio and long-term competitiveness. The expansion plan includes a calibrated and phased approach, with the R-32 project slated for commissioning by October 2026. The HFO manufacturing facility, for which an investment of approximately ₹200 crore is planned, is expected to commence work in 2027.
The Rajasthan project is anticipated to be eligible for incentives under RIPS-2024, potentially covering up to 100% of the eligible fixed capital investment through various subsidies and support mechanisms. These strategic initiatives underpin the company's confidence in achieving a targeted 30–35% revenue CAGR over the next three years and strengthening India's self-reliance in specialty chemicals.
What to do with a filing like this
Stallion India Fluorochemicals Limited filed this with the NSE as a statutory disclosure, categorised under capex. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Stallion India Fluorochemicals Limited. Read the original for the full detail.